Refractory Celiac Disease Successfully Treated With Azathioprine

Area of Science:

• Gastroenterology
• Immunology
• Dietary Medicine

Background:

• Refractory celiac disease (RCD) is defined by persistent symptoms, lab abnormalities, or villous atrophy in celiac disease (CD) patients despite a strict gluten-free diet (GFD) for 6-12 months.
• RCD should be suspected in CD patients with primary or secondary non-response to a GFD, particularly if significant weight loss is present.

Observation:

• Villous atrophy and persistent symptoms indicate RCD.
• Failure to respond to a gluten-free diet is a key diagnostic indicator.

Findings:

• Differentiating between Type I and Type II RCD is crucial for prognosis and management.
• Type I RCD can be managed with mild immunosuppression and nutritional support.
• Type II RCD necessitates aggressive immunosuppression (e.g., azathioprine) or, recently, autologous stem cell transplantation.

Implications:

• Accurate diagnosis and classification of RCD are essential for effective patient treatment.
• Tailored therapeutic strategies based on RCD type can improve patient outcomes.
• Emerging treatments like stem cell transplantation offer new hope for severe RCD cases.